Evidence map›Paper›PMID 41870123›Full record

ArticleAntimicrobial agents and chemotherapy2026

Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection.

Traian Sulea, Matthew Stuible, Maria Moreno, Alex Pelletier, Martin A Rossotti, Yuneivy Cepero-Donates, Jacqueline Slinn, Patrick Salois, Anh Tran, Melissa Hewitt and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Traian SuleaHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.ORCID 0000-0001-5301-8261
Matthew StuibleHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
Maria MorenoHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Alex PelletierHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
Martin A RossottiHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Yuneivy Cepero-DonatesHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
Jacqueline SlinnHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Patrick SaloisHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
Anh TranHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Melissa HewittHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Alvaro YogiHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Nazanin RohaniHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
Brian CassHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
Anne E G LenferinkHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
Jamshid TanhaHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Binbing LingHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Etienne LessardHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
Laurence DelafosseHuman Health Therapeutics Research Centre, National Research Council Canada, Montreal, Quebec, Canada.
Jagdeep K SandhuHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.
Danica StanimirovicHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronaviruses use the ACE2 receptor for viral entry while downregulating its activity, potentially leading to hypertension and major organ injuries. Dual-action technologies based on soluble ACE2 aimed to neutralize the virus while restoring ACE2's normal enzymatic activity. Here, we describe a novel general molecular design, VHH

Indexed as

Angiotensin-Converting Enzyme 2Antiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2Single-Domain AntibodiesAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19CricetinaeHumansMiceSpike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralAntiviral AgentsSingle-Domain AntibodiesSpike Glycoprotein, CoronavirusACE2 enzyme activityalbumin bindingblood pressure reductionCOVID-19single-domain antibodyspike proteinvirus neutralization

Identifiers

PMID41870123
PMCPMC13148018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.